Fluoxetine-tranylcypromine

From Psychiatrienet
Revision as of 12:29, 8 March 2024 by Ken (talk | contribs)
Jump to: navigation, search
Fluoxetine
Type Antidepressant
Group SSRI
links
Medscape Fluoxetine
PubChem 3386
PubMed Fluoxetine
Kompas (Dutch) Fluoxetine
Wikipedia Fluoxetine
Tranylcypromine
Type Antidepressant
Group MAO-I
links
Medscape Tranylcypromine
PubChem 5530
PubMed Tranylcypromine
Kompas (Dutch) Tranylcypromine
Wikipedia Tranylcypromine

Switch medication from fluoxetine to tranylcypromine.[1] [2]

Nietinrijdenbord.png Stop fluoxetine
  • Before day 1: reduce dosage of fluoxetine with about 20 mg per week.
  • Day 1: when a dosage of 20 mg/day is reached, stop fluoxetine.
  • a wash-out period of five weeks is necessary because of the long half live.
Eenrichtingbord.png Start tranylcypromine
  • a wash-out period of five weeks is necessary because of the long half live.
  • Day 36: start tranylcypromine in a low dosage of 20 mg/day for one week.
  • Day 43: after this week gradually increase the dosage of tranylcypromine.
Letopbord.png Cave
Infobord.png More information
  • Desmethylfluoxetine has a half live of about one week so a long wash-out period is necessary.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.